Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TSH BiopharmROCO:8432 84 Net Margin % is 6.67% as of Dec. 2025, which is 41% below its 10-year median of 11.30. GuruFocus rates ROCO:8432 with a GF Score™ of 84/100 and a GF Value™ of NT$78.92 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 962 Drug Manufacturers companies, TSH Biopharm ranks better than 65.7% on this metric.
Net margin is calculated as Net Income divided by its Revenue. TSH Biopharm's Net Income for the
three
months ended in Dec. 2025 was NT$24 Mil. TSH Biopharm's Revenue for the
three
months ended in Dec. 2025 was NT$358 Mil. Therefore, TSH Biopharm's net margin for the quarter that ended in Dec. 2025 was 6.67%.
The historical rank and industry rank for TSH Biopharm's Net Margin % or its related term are showing as below:
ROCO:8432'
s Net Margin % Range Over the Past 10 Years
Min: 7.64 Med: 11.3 Max: 28.67
Current: 10.42
ROCO:8432's Net Margin % is ranked better than 65.7% of 962
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs ROCO:8432: 10.42
TSH Biopharm (ROCO:8432) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
TSH Biopharm Net Margin % Related Terms
TSH Biopharm Net Margin % Historical Data
* Premium members only.
The historical data trend for TSH Biopharm's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, TSH Biopharm's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TSH Biopharm Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TSH Biopharm's Net Margin % distribution charts can be found below:
* The bar in red indicates where TSH Biopharm's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSH Biopharm (ROCO:8432) has a Net Margin % of 6.67% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on TSH Biopharm and its competitors. This is 41% below median its historical median of 11.30. Over the past decade, TSH Biopharm's Net Margin % has ranged from 7.64 to 28.67. According to the industry distribution chart, TSH Biopharm ranks #330 out of 962 companies in the Drug Manufacturers industry, placing it in the top 34.3%.
Is TSH Biopharm's Net Margin % too high?
TSH Biopharm's current Net Margin % of 6.67% is 41% below median its 10-year median of 11.30. Over the past 10 years, this metric has ranged from a low of 7.64 to a high of 28.67. The Drug Manufacturers industry median Net Margin % is 5.56. TSH Biopharm's value of 6.67% is 20% above this industry median. Based on the distribution chart, TSH Biopharm ranks #330 out of 962 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, TSH Biopharm has a GF Score™ of 84/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TSH Biopharm's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, TSH Biopharm ranks #330 out of 962 companies for Net Margin %. This puts TSH Biopharm in the upper half of its industry. The industry median Net Margin % is 5.56. TSH Biopharm's value of 6.67% is 20% above this benchmark. Historically, TSH Biopharm's own Net Margin % has ranged from 7.64 to 28.67 over the past decade. While the company's 10-year median is 11.30 vs. the industry median of 5.56, TSH Biopharm has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TSH Biopharm's current Net Margin % of 6.67% is 20% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on TSH Biopharm and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TSH Biopharm's current Net Margin % is 6.67%, which is 41% below median its own 10-year median of 11.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TSH Biopharm stock overvalued right now?
Based on GuruFocus' analysis, TSH Biopharm (ROCO:8432) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$78.92, compared to a current price of NT$50.20 — trading 36.4% below its estimated fair value. The current Net Margin % is 6.67%, which is 41% below median its 10-year median of 11.30 and 20% above the Drug Manufacturers industry median of 5.56. TSH Biopharm's overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For TSH Biopharm (ROCO:8432), the current Net Margin % is 6.67% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TSH Biopharm (ROCO:8432) Overvalued in 2026?
Based on GuruFocus' analysis, TSH Biopharm stock appears to be undervalued.
The current stock price of NT$50.20 is trading 36.4% below its estimated GF Value™ of NT$78.92.
GuruFocus considers TSH Biopharm to be Significantly Undervalued.
Key valuation signals for ROCO:8432:
Net Margin %: 6.67% (41% below median its 10-year median of 11.30)
GF Value™: NT$78.92 vs. price of NT$50.20 (36.4% below fair value)
Industry Position: 20% above the Drug Manufacturers median (#330 of 962)
No single metric tells the full story. See the ROCO:8432 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TSH Biopharm Corp Ltd is engaged in sale of a variety of pharmaceuticals, chemical drugs and engaged in biotechnology services. The company specializes in the development, manufacture, and marketing of branded drugs for chronic diseases. Key therapeutic areas include cardiovascular, central nervous system, gastroenterology, and severe chronic diseases, alongside precision medicine/genetic testing services .The Company's revenue is earned domestically. It earns majority of its revenue from the sale of Lozenges.
84GF Score
Get the complete analysis for ROCO:8432
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:8432 has been successfully added to your 
